Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

This collection describes the impact of pre-transplant molecular measurable residual disease (MRD) on acute myeloid leukemia (AML) prognosis. The original pre-MEASURE study demonstrated the ...

The median duration of response was 4.7 months, and 64% of tested patients were MRD-negative ... for relapsed or refractory (R/R) mNPM1 AML remains challenging, with chemotherapy and therapies ...

Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq ™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low ...

We believe these advancements could meaningfully accelerate the development and commercialization of ziftomenib in frontline AML with top-line results from the MRD-negative CR accelerated endpoint ...